乳腺癌的 Vulvar 转移用 Abemaciclib 加上 Fulvestrant 治疗:一个病例报告
Clémence Vanden Berghe1, Andoni Laka Antxustegi2, Nicole Nicaise1
1CHU UCL Namur Site Sainte-Elisabeth, Namur, Belgium.
Case reports in oncology
|March 4, 2026
概括
这项案例研究强调了使用循环素依赖性激酶4和6 (CDK4/6) 抑制剂和富勒韦斯特兰特治疗乳腺癌罕见的转移的成功治疗,在17年后实现完全缓解. 对于激素敏感乳腺癌患者来说,长期跟踪至关重要.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 阴道癌很少见,占女性癌症的不到1%.
- 转移性阴道瘤甚至更罕见,占阴道癌症的5-8%.
- 乳腺癌很少会转移到部.
研究的目的:
- 报告乳腺癌导致的阴道转移病例.
- 评估CDK4/6抑制剂和富尔韦斯特兰特在治疗这种罕见转移的疗效.
- 强调对激素敏感乳腺癌的长期随访的重要性.
主要方法:
- 一个78岁的女性的病例报告,在被诊断为乳腺癌17年后,她患有阴道转移.
- 通过PET扫描,临床检查和活检证实了诊断.
- 使用abemaciclib (一种CDK4/6抑制剂) 和富尔韦斯特兰特 (一种抗雌激素剂) 的治疗.
主要成果:
- 患者实现了完全的反应,并且仍然处于完全缓解状态.
- 使用组合疗法成功治疗阴道转移.
- 证明了有利的临床结果与最小的侵入性.
结论:
- 对激素敏感乳腺癌的长期随访至关重要.
- 与abemaciclib和fulvestrant的联合治疗对乳腺起源的阴道转移是有效的.
- CDK4/6抑制剂在治疗罕见的转移性部疾病方面取得了重大进展.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 20, 2019
05:02Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
相关概念视频
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...